Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2400 of 2529 entries
View as:

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Phase: N/A Priority: Normal
NCT ID: NCT02431481 Org: User:
Start: 10/23/15 End: 05/11/18 Due: 05/11/19

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03610724 Org: User:
Start: 02/15/19 End: 04/26/23 Due: 04/26/24

Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos

Phase: N/A Priority: Normal
NCT ID: NCT02543086 Org: User:
Start: 07/31/15 End: 09/30/15 Due: 09/30/16

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Phase: N/A Priority: Normal
NCT ID: NCT02257632 Org: User:
Start: 04/08/15 End: 06/08/17 Due: 06/08/18

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02947152 Org: User:
Start: 12/01/16 End: 09/14/17 Due: 09/14/18

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

Phase: N/A Priority: Normal
NCT ID: NCT02607813 Org: User:
Start: 01/18/16 End: 02/19/22 Due: 02/19/23

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

Phase: N/A Priority: Normal
NCT ID: NCT06797531 Org: User:
Start: 03/31/25 End: 11/30/28 Due: 11/30/29

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase: N/A Priority: Normal
NCT ID: NCT03524612 Org: User:
Start: 11/02/18 End: 10/03/22 Due: 10/03/23

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Phase: N/A Priority: Normal
NCT ID: NCT03907878 Org: User:
Start: 04/13/19 End: 01/26/22 Due: 01/26/23

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03020199 Org: User:
Start: 03/27/17 End: 06/16/23 Due: 06/16/24

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03839823 Org: User:
Start: 02/25/19 End: 05/10/23 Due: 05/10/24

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

Phase: N/A Priority: Normal
NCT ID: NCT03275064 Org: User:
Start: 09/12/17 End: 09/06/22 Due: 09/06/23

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Phase: N/A Priority: Normal
NCT ID: NCT06785779 Org: User:
Start: 01/30/25 End: 01/30/26 Due: 01/30/27

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00088608 Org: User:
Start: 04/30/04 End: - Due: -

Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

Phase: N/A Priority: Normal
NCT ID: NCT01396083 Org: User:
Start: 08/31/11 End: 01/31/14 Due: 01/31/15

A Phase I Study of LFA102 in Japanese Patients

Phase: N/A Priority: Normal
NCT ID: NCT01610050 Org: User:
Start: 06/30/12 End: 02/28/14 Due: 02/28/15

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Phase: N/A Priority: Normal
NCT ID: NCT01590199 Org: User:
Start: 05/18/12 End: 09/11/18 Due: 09/11/19

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05544929 Org: User:
Start: 10/26/22 End: 09/01/27 Due: 09/01/28

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Phase: N/A Priority: Normal
NCT ID: NCT01022996 Org: User:
Start: 12/31/09 End: 11/30/14 Due: 11/30/15

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Phase: N/A Priority: Normal
NCT ID: NCT06858319 Org: User:
Start: 07/28/25 End: 06/25/31 Due: 06/25/32

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05868629 Org: User:
Start: 02/06/24 End: 05/04/28 Due: 05/04/29

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04873934 Org: User:
Start: 06/24/21 End: 08/07/24 Due: 08/07/25

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Phase: N/A Priority: Normal
NCT ID: NCT03055494 Org: User:
Start: 04/18/17 End: 02/26/19 Due: 02/26/20

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01752634 Org: User:
Start: 04/14/13 End: 01/09/19 Due: 01/09/20

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT02663752 Org: User:
Start: 05/30/16 End: 07/01/16 Due: 07/01/17